menu
    • menu
    [{"orgOrder":0,"company":"Vasa Therapeutics","sponsor":"NuFund Venture Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"VS-041","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Vasa Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Vasa Therapeutics \/ NuFund Venture Group","highestDevelopmentStatusID":"5","companyTruncated":"Vasa Therapeutics \/ NuFund Venture Group"},{"orgOrder":0,"company":"Vasa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"VS-041","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Vasa Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Vasa Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vasa Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Vasa Therapeutics

    Menu

    Vasa Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vasa Therapeutics

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Vasa Therapeutics

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VS-041

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vasa Therapeutics’ Lead Drug Candidate Enters Clinical Trials

                            Details : VS-041 is an oral compound, which has potential treatment of HFpEF. It robustly reduces cardiac fibrosis and significantly improves diastolic heart functions.

                            Brand Name : VS-041

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 09, 2024

                            Lead Product(s) : VS-041

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vasa Therapeutics

                            U.S.A arrow
                            Duphat
                            Not Confirmed

                            Vasa Therapeutics

                            U.S.A arrow
                            Duphat
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VS-041

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : IND Enabling

                            Sponsor : NuFund Venture Group

                            Deal Size : $6.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Vasa Therapeutics Closes Seed Financing for Cardiovascular Aging Therapies

                            Details : The net proceeds will be used to advance novel therapies for cardiovascular aging, including VS-041, the first potential personalized medicine-based treatment of HFpEF.

                            Brand Name : VS-041

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 03, 2024

                            Lead Product(s) : VS-041

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : NuFund Venture Group

                            Deal Size : $6.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth